Telisotuzumab Adizutecan

Antibody–drug conjugate

Also known as ABBV-400

Phase 3underway

Evidence outlook · registrational

Non-Small Cell Lung Cancer: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2030-09.

Also in development:Advanced Metastatic Colorectal Cancer · Phase 3Colorectal Cancer · Phase 3

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Phase 2/3 (3)
Phase 2 (10)
Advanced Metastatic Colorectal Cancer
Colorectal Cancer
NCT07895355 · RemeGen Co., Ltd.
2026-11 – 2030-01 · Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy
What this study did
Non-Small Cell Lung Cancer
NCT07874282 · RemeGen Co., Ltd.
2026-11 – 2029-02 · Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or Cytology
What this study did
Other / comorbidity
NCT06628310 · AbbVie
2024-12-13 – 2030-10 · Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
What this study did
NCT07769502 · AbbVie
2026-08-17 – 2028-09 · Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma
What this study did
Phase 1/2 (1)
Phase 1 (4)
Advanced Metastatic Colorectal Cancer
Non-Small Cell Lung Cancer
NCT05005403 · AbbVie
2021-11-01 – 2027-07 · Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer, High-Grade Serous Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer
What this study did
Other / comorbidity
NCT06084481 · AbbVie
2023-11-09 – 2027-09 · Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer, Head and Neck Squamous-Cell Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer
What this study did

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, 3 of them ahead of this one.

This drug's own stage for Advanced Metastatic Colorectal Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Telisotuzumab Adizutecan: this drugPhase 3Antibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
EncorafenibApprovedSmall moleculeBRAF V600Enot yet gradedNo reviewed efficacy summary in this indication
Fruquintinib (Fruzaqla / Elunate)ApprovedSmall moleculeVEGFR1/2/3Reliable signal
NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Weak signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7)
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)Reliable signal
NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016)
SotorasibApprovedSmall moleculeKRAS G12Cnot yet gradedNo reviewed efficacy summary in this indication
TucatinibApprovedSmall moleculeHER2Partial signal
NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BafisontamabPhase 2Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
PelareorepPhase 2Oncolytic virusTumor cells (oncolytic replication)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(20 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Telisotuzumab Adizutecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Advanced Metastatic Colorectal CancerActive not recruiting
Est. primary completion 2026-12 · NCT06107413 · CT.gov ↗
What to watch
2027 (7)
July 2027 (1)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-07 · NCT05005403 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Advanced Metastatic Colorectal CancerActive not recruiting
Est. primary completion 2027-08 · NCT06614192 · CT.gov ↗
What to watch
September 2027 (1)
Phase 1Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma …Recruiting
Est. primary completion 2027-09 · NCT06084481 · CT.gov ↗
What to watch
November 2027 (2)
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-11 · NCT05029882 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-11 · NCT06772623 · CT.gov ↗
What to watch
December 2027 (2)
Phase 1Advanced Metastatic Colorectal CancerActive not recruiting
Est. primary completion 2027-12 · NCT06464692 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12 · NCT07874282 · CT.gov ↗
What to watch
2028 (3)
March 2028 (1)
Phase 2Advanced Metastatic Colorectal CancerRecruiting
Est. primary completion 2028-03 · NCT06820463 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2028-07 · NCT07895355 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Pancreatobiliary Cancers, Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2028-09 · NCT07769502 · CT.gov ↗
What to watch
2029 (3)
May 2029 (1)
Phase 3Advanced Metastatic Colorectal CancerRecruiting
Est. primary completion 2029-05 · NCT07525206 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2029-10 · NCT07744126 · CT.gov ↗
What to watch
November 2029 (1)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2029-11 · NCT07023289 · CT.gov ↗
What to watch
2030 (4)
March 2030 (1)
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2030-03 · NCT07821684 · CT.gov ↗
What to watch
September 2030 (1)
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-09 · NCT07155187 · CT.gov ↗
What to watch
October 2030 (1)
Phase 2Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal AdenocarcinomaActive not recruiting
Est. primary completion 2030-10 · NCT06628310 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Solid Tumors Harboring MET AmplificationRecruiting
Est. primary completion 2030-12 · NCT07196644 · CT.gov ↗
What to watch
2031 (1)
June 2031 (1)
Phase 2/3Metastatic Pancreatic Ductal Adenocarcinoma, PDACRecruiting
Est. primary completion 2031-06 · NCT07490301 · CT.gov ↗
What to watch
2036 (1)
November 2036 (1)
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2036-11 · NCT07005102 · CT.gov ↗
What to watch

See the full readout calendar ↗